The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and
DLX1 urinary markers combined in the improvement of prostate
cancer diagnostics

J 2023

The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics

MYTSYK, Yulian, Yosyf NAKONECHNYI, Victor DOSENKO, Pawel KOWAL, Michal PIETRUS et. al.

Basic information

Original name

The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics

Authors

MYTSYK, Yulian, Yosyf NAKONECHNYI, Victor DOSENKO, Pawel KOWAL, Michal PIETRUS, Katarina GAZDIKOVA, Monika LABUDOVA, Martin CAPRNDA, Robert PROSECKÝ (203 Czech Republic, belonging to the institution), Jozef DRAGASEK, Peter KRUŽLIAK (703 Slovakia, guarantor, belonging to the institution) and Roman DATS

Edition

Clinical Biochemistry, OXFORD, PERGAMON-ELSEVIER SCIENCE LTD, 2023, 0009-9120

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.800 in 2022

RIV identification code

RIV/00216224:14110/23:00131199

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.clinbiochem.2023.04.011

UT WoS

001005720800001

Keywords in English

Prostate cancer; Diagnostics; RNA; PCA3; TMPRSS2; ERG; HOXC6; DLX1; Urinary marker

Abstract

V originále

Background: Prostate cancer (PCa) is the second most commonly diagnosed cancer in men. To date, the role of the combined application of long non-coding RNAs (PCA3, DLX1, HOXC6, TMPRSS2:ERG) for obtaining the most accurate method of detection of PCa has not yet been comprehensively investigated.Methods: In total 240 persons were included in the retrospective study. Among them were 150 patients with confirmed PCa, 30 patients with benign prostatic hyperplasia, 30 patients with active chronic prostatitis and 30 healthy volunteers. In all patients, the urine samples were collected prior to biopsy or treatment. Polymerase chain reaction with reverse transcription was performed to detect the expression level of PCA3, HOXC6, DLX1 and the presence of the TMPRSS2:ERG transcript.Results: PCA3 was detected in urine samples in all cases. Using a PCA3 score of 56 allowed the differentiation between PCa and all other cases with a sensitivity of 61% and specificity of 96% (p < 0.001) while a PCA3 score threshold value of 50 resulted in a differentiation between clinically significant PCa (ISUP grades 2-5) and all other cases with a sensitivity of 93% and specificity of 93% (p < 0.001). The TMPRSS2:ERG expression in urine was detected exclusively in the group of patients with PCa and only in 16% of all cases.Conclusions: PCA3 score detected in urine demonstrated moderate sensitivity and good specificity in differenti-ation between PCa and non-PCa and high sensitivity and specificity in differentiation between clinically sig-nificant PCa and non-PCa.

Citovat

MYTSYK, Yulian, Yosyf NAKONECHNYI, Victor DOSENKO, Pawel KOWAL, Michal PIETRUS, Katarina GAZDIKOVA, Monika LABUDOVA, Martin CAPRNDA, Robert PROSECKÝ, Jozef DRAGASEK, Peter KRUŽLIAK and Roman DATS. The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics. Clinical Biochemistry. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2023, vol. 116, June 2023, p. 120-127. ISSN 0009-9120. Available from: https://dx.doi.org/10.1016/j.clinbiochem.2023.04.011.

@article{2296986,
   author = {Mytsyk, Yulian and Nakonechnyi, Yosyf and Dosenko, Victor and Kowal, Pawel and Pietrus, Michal and Gazdikova, Katarina and Labudova, Monika and Caprnda, Martin and Prosecký, Robert and Dragasek, Jozef and Kružliak, Peter and Dats, Roman},
   article_location = {OXFORD},
   article_number = {June 2023},
   doi = {http://dx.doi.org/10.1016/j.clinbiochem.2023.04.011},
   keywords = {Prostate cancer; Diagnostics; RNA; PCA3; TMPRSS2; ERG; HOXC6; DLX1; Urinary marker},
   language = {eng},
   issn = {0009-9120},
   journal = {Clinical Biochemistry},
   title = {The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics},
   url = {https://www.sciencedirect.com/science/article/pii/S0009912023000838?via%3Dihub},
   volume = {116},
   year = {2023}
}

TY  - JOUR
ID  - 2296986
AU  - Mytsyk, Yulian - Nakonechnyi, Yosyf - Dosenko, Victor - Kowal, Pawel - Pietrus, Michal - Gazdikova, Katarina - Labudova, Monika - Caprnda, Martin - Prosecký, Robert - Dragasek, Jozef - Kružliak, Peter - Dats, Roman
PY  - 2023
TI  - The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics
JF  - Clinical Biochemistry
VL  - 116
IS  - June 2023
SP  - 120-127
EP  - 120-127
PB  - PERGAMON-ELSEVIER SCIENCE LTD
SN  - 00099120
KW  - Prostate cancer
KW  - Diagnostics
KW  - RNA
KW  - PCA3
KW  - TMPRSS2
KW  - ERG
KW  - HOXC6
KW  - DLX1
KW  - Urinary marker
UR  - https://www.sciencedirect.com/science/article/pii/S0009912023000838?via%3Dihub
N2  - Background: Prostate cancer (PCa) is the second most commonly diagnosed cancer in men. To date, the role of the combined application of long non-coding RNAs (PCA3, DLX1, HOXC6, TMPRSS2:ERG) for obtaining the most accurate method of detection of PCa has not yet been comprehensively investigated.Methods: In total 240 persons were included in the retrospective study. Among them were 150 patients with confirmed PCa, 30 patients with benign prostatic hyperplasia, 30 patients with active chronic prostatitis and 30 healthy volunteers. In all patients, the urine samples were collected prior to biopsy or treatment. Polymerase chain reaction with reverse transcription was performed to detect the expression level of PCA3, HOXC6, DLX1 and the presence of the TMPRSS2:ERG transcript.Results: PCA3 was detected in urine samples in all cases. Using a PCA3 score of 56 allowed the differentiation between PCa and all other cases with a sensitivity of 61% and specificity of 96% (p < 0.001) while a PCA3 score threshold value of 50 resulted in a differentiation between clinically significant PCa (ISUP grades 2-5) and all other cases with a sensitivity of 93% and specificity of 93% (p < 0.001). The TMPRSS2:ERG expression in urine was detected exclusively in the group of patients with PCa and only in 16% of all cases.Conclusions: PCA3 score detected in urine demonstrated moderate sensitivity and good specificity in differenti-ation between PCa and non-PCa and high sensitivity and specificity in differentiation between clinically sig-nificant PCa and non-PCa.
ER  -

MYTSYK, Yulian, Yosyf NAKONECHNYI, Victor DOSENKO, Pawel KOWAL, Michal PIETRUS, Katarina GAZDIKOVA, Monika LABUDOVA, Martin CAPRNDA, Robert PROSECKÝ, Jozef DRAGASEK, Peter KRUŽLIAK and Roman DATS. The performance and limitations of PCA3, TMPRSS2:ERG, HOXC6 and DLX1 urinary markers combined in the improvement of prostate cancer diagnostics. \textit{Clinical Biochemistry}. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD, 2023, vol.~116, June 2023, p.~120-127. ISSN~0009-9120. Available from: https://dx.doi.org/10.1016/j.clinbiochem.2023.04.011.

Detailed Information on Publication Record